Antibody-drug conjugates: an emerging modality for the treatment of cancer. - Wikidata - awgldk - TriplyDB

Antibody-drug conjugates: an emerging modality for the treatment of cancer.

Antibody-drug conjugates: an emerging modality for the treatment of cancer.

http://www.wikidata.org/entity/Q38239854

about

Antibody-drug conjugates as novel anti-cancer chemotherapeutics Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?Discovery of Anticancer Agents of Diverse Natural Origin Challenges and advances in the assessment of the disposition of antibody-drug conjugates Therapeutic aptamers: developmental potential as anticancer drugs Quantitative assessment of antibody internalization with novel monoclonal antibodies against Alexa fluorophores Targeted Delivery of Deoxycytidine Kinase to Her2-Positive Cells Enhances the Efficacy of the Nucleoside Analog Fludarabine Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy Classification of current anticancer immunotherapies A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies.Marine Peptides: Bioactivities and Applications Sequence-Defined Oligomers from Hydroxyproline Building Blocks for Parallel Synthesis Applications.Intracellular GSH-activated galactoside photosensitizers for targeted photodynamic therapy and chemotherapy.Antibody Therapeutics in Oncology.The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer.Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.Photochemical activation of drugs for the treatment of therapy-resistant cancers.Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors.Antibody-targeted nanoparticles for cancer treatment.Antisense oligonucleotide and thyroid hormone conjugates for obesity treatment Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.The control of tumor vessels: what you would not expect from a neural adhesion molecule.A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer.Peptides and Drug Delivery.Antibody Labeling with Fluorescent Dyes Using Magnetic Protein A and Protein G Beads.Calculated conjugated payload from immunoassay and LC-MS intact protein analysis measurements of antibody-drug conjugate.Mechanically interlocked functionalization of monoclonal antibodies.Therapeutic Properties and Biological Benefits of Marine-Derived Anticancer Peptides.Use of a charge reducing agent to enable intact mass analysis of cysteine-linked antibody-drug-conjugates by native mass spectrometry.

P2860

Q26800175-EEBECBE3-1C5E-4F83-9F71-2B3E6C3B67C1 Q28067696-395173B5-3C7C-49FA-85EB-504511D884E2 Q28068341-DB32F659-369F-4D88-89DF-376A764475A6 Q28085074-3F0A7F0A-1AFB-47AD-853B-1D996954A8B5 Q28085157-90CC8668-8BEF-47B5-832D-55F7074C9C08 Q28546526-25C79522-A008-419E-8B3A-86CEE95F8228 Q28550176-5D3A3B27-DDFC-43EF-B4DE-C14B7C22A189 Q33802940-E46AF638-778C-4F0E-AC92-D340BC4FEA15 Q35149637-EB871469-F8C2-4C38-98EA-2195140DFD8E Q35764587-2FF2EE86-8610-40A9-99BA-A53D0752A253 Q35890691-02B6EBDF-0591-4E43-8ADD-0D5F45A5CACF Q36065500-892E8AE5-20A6-4444-BD80-E4560C7BCFC7 Q36220307-D5CFE45B-FAC3-45A7-BFF0-3894341AE325 Q36791878-49B3554B-772D-4D72-901D-458551F8D056 Q37269458-759853FA-F0A7-48AF-ADF5-5F318278D9D3 Q37367593-B5B356B2-C8E5-4085-8E21-E454B18D6F5E Q38409528-63B852BA-E143-4FE6-9CA5-7BA5F2FCEAAB Q38659065-ED78C6EB-EF2B-44DC-9437-A67D4AC5577A Q38887307-F56E5AB5-2B4A-431C-995E-9E6A7A4AAF14 Q41517624-8C4C318E-A058-44BB-9601-08632052C48C Q42499937-B9C0C427-B0BE-4602-9AE7-EDA428D5A717 Q42558833-C4129AEB-A1BE-4F8E-8728-634B989F2423 Q42732155-7161DD78-5FD3-4893-AF45-BB5312BEDC1D Q47104633-98083F4F-0A56-4D78-9131-418F678BFEE9 Q47590591-4683B1DB-430B-4926-833B-2049AA23B6E7 Q51449237-C60EEF8D-B948-4996-9F2B-F110C41EC8B3 Q51451422-EF67D38B-2B7C-443C-98F1-11DF84982124 Q52313806-064E7BD3-987F-4F3A-91A3-07DACB8DA1BA Q52646693-A3AB07B1-3720-4838-9DB7-9234D1318C56 Q55425586-213E0363-1A88-46FF-8F0A-7F33D88A7A47

P2860

Antibody-drug conjugates: an emerging modality for the treatment of cancer.

http://www.wikidata.org/entity/Q38239854

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Antibody-drug conjugates: an emerging modality for the treatment of cancer.

@en

type

label

Antibody-drug conjugates: an emerging modality for the treatment of cancer.

@en

prefLabel

Antibody-drug conjugates: an emerging modality for the treatment of cancer.

@en

P1433

Q38239854-BA1F3F59-4A2B-4AAB-BBED-E77A93FD61C4

P1476

Q38239854-BBC58E32-F5F5-40DF-A4E8-975317B090F5

P2093

Q38239854-0BCBE0A3-425C-400E-865D-60F2C0A9485A

Q38239854-415B015E-701B-4A14-948D-3EF0EA4FED71

Q38239854-5F2F0EDE-5122-4635-BBF1-A7334C224E0C

Q38239854-868B80B8-FEC2-420B-A232-BD16C65E0819

Q38239854-9AF88527-37BA-42E9-ACDD-890E6415DCC5

Q38239854-CB38D1DE-860D-46B8-AEEA-17D7CA568C43

Q38239854-CC353E29-B96F-4801-B09A-A210EC749489

Q38239854-E70573DC-7D96-4659-A245-EADEFE1E86C4

Q38239854-EF006115-B171-4093-828E-9EEC76889E10

P2860

Q38239854-0229E90A-917E-44A2-9262-C0F836BB174E

Q38239854-0365169C-2334-44F3-9CB4-0B19F5CA8818

Q38239854-05D5FB58-AF2D-4B15-AE05-CDBA3FE6C63F

Q38239854-0FE687F2-065D-4856-9DCE-076B28636E2F

Q38239854-12339761-677C-4175-8B40-F4B910132714

Q38239854-205F051A-04D3-4115-AE4C-8141D9C41E24

Q38239854-213F1BA5-F3FD-4B4D-B184-7756A0FF5EF2

Q38239854-2B768D3B-A26E-4B50-82C1-766944897CF2

Q38239854-334F75C2-342D-48A0-A074-1BD2F97D0892

Q38239854-50995E8A-0347-4F3F-B5C8-D5E0FF8F19F6

P304

Q38239854-2887982F-698C-4E93-BC88-372FB2A0E908

P31

Q38239854-016B52D1-CE8F-40BF-90B5-B40344B1860D

P356

Q38239854-D65D354E-B505-48C9-B7CB-6A3E924C5EC7

P407

Q38239854-74B6F0AA-3609-4379-A48F-C80D24F547A7

P478

Q38239854-E213FF44-095E-4C99-84C8-3F21F84B459C

P577

Q38239854-489BF5D9-AC57-4516-A0DD-5EE0033E3D3D

P698

Q38239854-34200ACB-F3F0-45A3-B96C-2670D0AF0F07

P921

Q38239854-CEB8A482-12F8-4B7B-A0D1-5790155DF67F

P356

P1433

Annals of the New York Academy of Sciences

P1476

Antibody-drug conjugates: an emerging modality for the treatment of cancer.

@en

P2093

Alan Wahl

http://www.w3.org/2001/XMLSchema#string

Dhaval K Shah

http://www.w3.org/2001/XMLSchema#string

Mauricio Leal

http://www.w3.org/2001/XMLSchema#string

Melissa Schutten

http://www.w3.org/2001/XMLSchema#string

Nahor Haddish-Berhane

http://www.w3.org/2001/XMLSchema#string

Omar Kabbarah

http://www.w3.org/2001/XMLSchema#string

Peter Senter

http://www.w3.org/2001/XMLSchema#string

Puja Sapra

http://www.w3.org/2001/XMLSchema#string

Sara A Hurvitz

http://www.w3.org/2001/XMLSchema#string

P2860

STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors

Tissue distribution studies of protein therapeutics using molecular probes: molecular imaging

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Identification of stem cells in small intestine and colon by marker gene Lgr5

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate

P304

41-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/NYAS.12499

http://www.w3.org/2001/XMLSchema#string

P407

P478

1321

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25123209

http://www.w3.org/2001/XMLSchema#string

P921